SPRING-1 at a glance
A short narrated summary of the pivotal trial design, primary endpoint and safety profile, with on-screen references.
Clinical and educational material on ▼DEMOZUMAB (vigilanafine) for the add-on maintenance treatment of moderate-to-severe allergic rhinitis in adults and adolescents 12 years and older whose disease is inadequately controlled despite treatment with intranasal corticosteroids.3
Each item below is a piece of promotional or educational material in a different format. Open it in the viewer, or download it to review in Siguru.
A short narrated summary of the pivotal trial design, primary endpoint and safety profile, with on-screen references.
A promotional email to UK prescribers announcing the publication of the SPRING-1 primary results.
A short product page for UK healthcare professionals with the licensed indication, SPRING-1 headline results and dosing.
An unbranded public campaign page on the symptoms, triggers and impact of allergic rhinitis, and when to get help, organised and funded by Siguru Limited.
The speaker programme slide deck on the pivotal trial, with study design, endpoints, subgroups and safety tables.
A short slide set covering the indication, mechanism, dosing and the SPRING-1 results table, for use in one-to-one meetings.
Please refer to the Summary of Product Characteristics before prescribing DEMOZUMAB.
View prescribing informationUK-DMB-2026-014 | Date of preparation: October 2026